{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Perjeta&page=2", "query": { "intervention": "Perjeta", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Perjeta&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-21T07:35:26.156Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01121939", "title": "Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Sandostatin LAR® Depot", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2010-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-02-05", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 9, "location_summary": "Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01121939" }, { "nct_id": "NCT07459673", "title": "HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-positive Breast Cancer", "Breast Cancer Stage IV" ], "interventions": [ { "name": "Personalis NeXT Personal", "type": "DIAGNOSTIC_TEST" }, { "name": "Natera Signatera", "type": "DIAGNOSTIC_TEST" }, { "name": "fam-trastuzumab deruxtecan-nxki (T-DXd)", "type": "DRUG" }, { "name": "pertuzumab, called T-DXd+P", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-03-04", "completion_date": "2030-03-04", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07459673" }, { "nct_id": "NCT02060253", "title": "Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "ganetespib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "pertuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-04", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2018-06-14", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02060253" }, { "nct_id": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-03-23", "completion_date": "2027-01-15", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136897" }, { "nct_id": "NCT04425018", "title": "MARGetuximab Or Trastuzumab (MARGOT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Stage II Breast Cancer", "Stage III Breast Cancer", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Margetuximab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2020-07-13", "completion_date": "2027-07-01", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 14, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Foxborough, Massachusetts + 8 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Foxborough", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04425018" }, { "nct_id": "NCT03742986", "title": "Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Nivolumab 360mg", "type": "DRUG" }, { "name": "Paclitaxel 80mg/m^2", "type": "DRUG" }, { "name": "Doxorubicin 60mg/m^2", "type": "DRUG" }, { "name": "Cyclophosphamide 600mg/m^2", "type": "DRUG" }, { "name": "Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2", "type": "DRUG" }, { "name": "Trastuzumab 8mg/kg and 6 mg/kg", "type": "DRUG" }, { "name": "Pertuzumab 840mg and 420mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2019-05-02", "completion_date": "2023-06-12", "has_results": true, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 2, "location_summary": "Bloomington, Indiana • New York, New York", "locations": [ { "city": "Bloomington", "state": "Indiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03742986" }, { "nct_id": "NCT01730833", "title": "Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Breast Adenocarcinoma", "Inflammatory Breast Carcinoma" ], "interventions": [ { "name": "pertuzumab", "type": "BIOLOGICAL" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 63, "start_date": "2013-07-17", "completion_date": "2026-04-20", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 3, "location_summary": "Duarte, California • Lancaster, California • South Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730833" }, { "nct_id": "NCT04208178", "title": "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced HER2+Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Alpelisib matching Placebo", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 19, "start_date": "2020-07-16", "completion_date": "2027-02-26", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • Los Angeles, California", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04208178" }, { "nct_id": "NCT02336984", "title": "A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "HER-2 pulsed DC1", "type": "BIOLOGICAL" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "pertuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2014-06", "completion_date": "2016-04-04", "has_results": false, "last_update_posted_date": "2021-01-11", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 2, "location_summary": "Tampa, Florida • Philadelphia, Pennsylvania", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02336984" }, { "nct_id": "NCT02073487", "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "T-DM1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2014-02", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-09-21T07:35:26.156Z", "location_count": 3, "location_summary": "Houston, Texas • Sugar Land, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073487" } ] }